RMRyuichi Morishita

Ryuichi Morishita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ryuichi Morishita has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SP371SELECTIVE BLOCKADE OF PERIOSTIN EXON 17 PROTECTED FROM DEVELOPMENT OF RENAL FIBROSIS

    by Jun Muratsu, Fumihiro Sanada, Yoshiaki Taniyama, Rei Otsu, Hiromi Rakugi, Ryuichi Morishita

    INTRODUCTION AND AIMS: Renal fibrosis is the principal process underlying the progression of chronic kidney disease. Recently, it is suggested that periostin, extracellular matrix, is involved in the development of renal fibrosis through the modulation of TGF-β pathway. However, the existence and significance of alternative c-terminal splicing variants (ASVs) in periostin on the development of the renal fibrosis protection is unclear, since the variants of periostin are well known to have the different actions.

  • MPS 13-01 NOVEL THERAPEUTIC APPROACH FOR CEREBRAL ISCHEMIA IN RATS WITH ANGIOTENSIN II PEPTIDE VACCINE

    by Hironori Nakagami, Kouji Wakayama, Munehisa Shimamura, Jun-Ichi Suzuki, Ryo Watanabe, Hiroshi Koriyama, Mitsuaki Isobe, Hiromi Rakugi, Ryuichi Morishita

  • Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats

    by Hiroshi Koriyama, Hironori Nakagami, Futoshi Nakagami, Mariana Kiomy Osako, Mariko Kyutoku, Munehisa Shimamura, Hitomi Kurinami, Tomohiro Katsuya, Hiromi Rakugi, Ryuichi Morishita

    Recent research on vaccination has extended its scope from infectious diseases to chronic diseases, including Alzheimer disease, dyslipidemia, and hypertension. The aim of this study was to design DNA vaccines for high blood pressure and eventually develop human vaccine therapy to treat hypertension. Plasmid vector encoding hepatitis B core-angiotensin II (Ang II) fusion protein was injected into spontaneously hypertensive rats using needleless injection system. Anti-Ang II antibody was successfully produced in hepatitis B core-Ang II group, and antibody response against Ang II was sustained for at least 6 months. Systolic blood pressure was consistently lower in hepatitis B core-Ang II group after immunization, whereas blood pressure reduction was continued for at least 6 months. Perivascular fibrosis in heart tissue was also significantly decreased in hepatitis B core-Ang II group. Survival rate was significantly improved in hepatitis B core-Ang II group. This study demonstrated that Ang II DNA vaccine to spontaneously hypertensive rats significantly lowered high blood pressure for at least 6 months. In addition, Ang II DNA vaccines induced an adequate humoral immune response while avoiding the activation of self-reactive T cells, assessed by ELISPOT assay. Future development of DNA vaccine to treat hypertension may provide a new therapeutic option to treat hypertension.


    • 1 July 2014
      • Vol. 24  (7) , 53-62

    [Bone metabolism and cardiovascular function update. Cross link of hypertension, bone loss and vascular calcification - common back grounds in renin angiotensin system with anti-aging aspect -].

    by Hideo Shimizu, Hironori Nakagami, Ryuichi Morishita

    Hypertension, osteoporosis and vascular calcification are major diseases in the recent aging society and may share the same backgrounds genetically and environmentally. As treatments to prevent aging-related diseases simultaneously are desirable, we investigate common backgrounds underling these diseases. Renin- angiotensin system, which causes high blood pressure, is found to be involved in bone metabolism. Angiotensin II has been shown to accelerate osteoporosis through RANKL up-regulation in osteoblast. RANKL, in turn, contributes to vascular calcification by regulating bone morphogenetic protein-2 and MGP expression, as well as bone-related proteins. Angiotensin type 1 receptor blockers (ARBs) ameliorate osteoporosis and vascular calcification beyond their blood pressure lowering effects. These pleiotropic effects of antihypertensive drugs such as ARBs might benefit especially hypertensive postmenopausal women.


    • 1 April 2013
      • Vol. 23  (4) , 497-503

    [Hypertension and osteoporosis].

    by Hironori Nakagami, Ryuichi Morishita

    The number of patients with high blood pressure and osteoporosis are increased year by year in our society. In hypertension patients, excess urinary calcium secretion induces secondary parathyroidism to increase serum calcium level by calcium release from bone, which may accelerate osteoporosis. In this aspect, there are several reports that anti-hypertensive drugs, especially thiazides, increase bone mineral density and decrease the incidence of bone fracture. In addition, we demonstrated that renin-angiotensin system can be involved in the process of osteoporosis. Angiotensin II significantly induced the expression of RANKL (receptor activator of NF-κB ligand) in osteoblasts, leading to the activation of osteoclasts, while these effects were completely blocked by an Ang II type 1 receptor blockade. Recently, it has been reported that angiotensin receptor blockade clinically decreased the incidence of bone fracture. Renin-angiotensin system might be common molecule to regulate both hypertension and osteoporosis.


  • Olmesartan Reduces Pentosidine Production and Ameliorates Fragility of Bone in Ovariectomized Fructose-Fed Rats

    by Hideo Shimizu, Hironori Nakagami, Natsuki Yasumasa, Osako Kiomy Mariana, Ryuichi Morishita

    Recent epidemiological studies have demonstrated that diabetes mellitus (DM) is a risk factor for bone fracture. Both hyperglycemia and oxidative stress induce a reduction in enzymatic beneficial cross-links and the accumulation of disadvantageous non-enzymatic cross-linking by advanced glycation end products (AGEs) such as pentosidine in bone. On the other hand, some antihypertensive drugs have been reported to improve peripheral conditions such as retinopathy or kidney dysfunction induced by DM. In this study, ovariectomized rats with a high-fructose diet were treated with or without olmesartan, for investigating aspects of bone and mineral metabolism derangement in DM. High-fructose loading increased insulin resistance and serum pentosidine concentration. Immunohistochemical analysis also demonstrated pentosidine accumulation in bone. These results were in accordance with the results of a three point bending test, which revealed fragility of bone. Of interest, treatment with olmesartan improved insulin resistance and decreased the accumulation of the AGE pentosidine. Three point bending test also revealed improvement in fragility of bone induced by a highfructose diet. Overall, olmesartan treatment might be a useful approach in the treatment of hypertensive patients with DM.

  • Rosuvastatin Ameliorates Obesity and Proteinuria in Zucker Diabetic Fatty Rats

    by Hironori Nakagami, Takashi Shimosato, Munehisa Shimamura, Ryuichi Morishita

    Abstract: Obesity and metabolic syndrome are major risk factors for the development of atherosclerosis or chronic kidney disease. In this paper, we investigated the effect of rosuvastatin and atorvastatin on endothelial function, and liver and kidney function in obese fa/fa Zucker diabetic fatty (ZDF) rats. ZDF rats were administered rosuvastatin (10 mg/kg/day p.o.) or atorvastatin (10 mg/kg/day p.o.) for 12 weeks. Rosuvastatin treatment decreased body weight and fat weight. Neither statin affected the blood sugar and total cholesterol levels, whereas they led to a significant decrease in triglyceride and liver markers (AST and ALT). Rosuvastatin, but not atorvastatin, markedly reduced elevated urinary protein excretion after 12 weeks of treatment. Endothelial function, which was evaluated by EC50 values for acetylcholine-induced relaxation of mesenteric artery rings, was altered after 12 weeks of treatment with rosuvastatin, but not atorvastatin. Our findings suggest that rosuvastatin treatment may improve obesity, proteinuria and endothelial function compared with treatment with atorvastatin.


  • Open Access

    Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice

    by Futoshi Nakagami, Hiroshi Koriyama, Hironori Nakagami, Mariana Kiomy Osako, Munehisa Shimamura, Mariko Kyutoku, Takashi Miyake, Tomohiro Katsuya, Hiromi Rakugi, Ryuichi Morishita

    Vaccines have been recently developed to treat various diseases such as cancer, rheumatoid arthritis and Alzheimer’s disease in addition to infectious diseases. However, before use in the clinical setting, vaccines targeting self-antigens must be demonstrated to be effective and safe, evoking an adequate humoral immune response from B cells while avoiding T cell activation in response to self. Although the vaccine targeting angiotensin II (Ang II) is efficient in rodents and humans, little is known regarding the immunological activation and safety of the vaccine. In this study, we evaluated the efficiency and safety of an Ang II peptide vaccine in mice. Immunization with Ang II conjugated to keyhole limpet hemocyanin (KLH) successfully induced the production of anti-Ang II antibody, which blocked Ang II signaling in human aortic smooth muscle cells. However, Ang II itself did not activate T cells, as assessed by the proliferation and lymphokine production of T cells in immunized mice, whereas KLH activated T cells. In an Ang II-infused model, the non-immunized mice showed high blood pressure (BP), whereas the immunized mice (Ang II-KLH) showed a significant decrease in systolic BP, accompanied by significant reductions in cardiac hypertrophy and fibrosis. Importantly, anti-Ang II antibody titer was not elevated even after the administration of large amounts of Ang II, indicating that Ang II itself boosted antibody production, most likely due to less activation of T cells. In addition, no accumulation of inflammatory cells was observed in immunized mice, because endogenous Ang II would not activate T cells after immunization with Ang II-KLH. Taken together, these data indicate that vaccines targeting Ang II might be effective to decrease high BP and prevent cardiovascular complications without severe side effects.


  • Chronic Deposition of Aβ Influences Microcirculation in the Chronic Stage of Cerebral Ischemia

    by Munehisa Shimamura, Naoyuki Sato, Hironori Nakagami, Mariana Kiomy Osako, Mariko Kyutoku, Kouji Wakayama, Ryuichi Morishita

    Although the linkage between vascular dysfunction and Alzheimer’s disease has received much attention, the influence of beta-amyloid (Aβ) deposits on microcirculation in the chronic stage of ischemic brain injury is unknown. To examine the relationship of Aβ with the microcirculation around Aβ deposits in the chronic stage of cerebral infarction, Wistar rats were exposed to permanent middle cerebral artery occlusion (MCAo). Microangiography using albuminfluorescein isothiocyanate was performed 3 months after MCAo, followed by immunohistochemistry with GFAP and Aβ. Two types of atrophic changes were observed in the thalamus of ischemic brains: mild atrophy and severe atrophy with tissue defects. In both types, the deposition of Aβ was observed in the ventroposterior lateral and ventroposterior medial nuclei of the thalamus. Although various patterns of microcirculation were observed in the thalamus, a high density of enlarged microvessels with reactive gliosis was often observed around Aβ deposits. Conversely, enlarged low-density microvessels with less reactive gliosis were observed in the Aβ deposits. Because the regions with reactive gliosis without Aβ deposits showed no changes in microcirculation and previous reports showed the proangiogenic and anti-angiogenic effects of Aβ in in vitro studies, we hypothesize that continuous Aβ deposits act directly on microvessels, rather than via reactive gliosis. Although further studies are necessary, therapeutic approaches to reduce Aβ deposits might be a promising approach to improve microcirculation in the thalamus in the chronic stage of ischemic stroke.

    • 1 September 2012
      • Vol. 70  (9) , 1524-9

    [Activation of osteoclasts by RAAS and strategy of target therapy on bone metabolic diseases].

    by Hideo Shimizu, Hironori Nakagami, Ryuichi Morishita

    Angiotensin II is a potent stimulator of vascular smooth mustle cells that increases blood pressure, and angiotensin type 1 receptors have been identified on osteoblasts; thus, the renin-angiotensin system has been suggested to be involved in bone metabolism. The authors reported that angiotensin II significantly increased TRAP-positive multinuclear osteoclasts with the up-regulation of RANKL expression through extracellular kinase of osteoblast. These effects were abolished with co-treatment of angiotensin converting enzyme (ACE) inhibitors or angiotensin type 1 receptor blockers (ARB). Recently, RANK-RANKL-OPG system is proved to be involved in vascular calcification and RAAS also might be involved in the development of the disease. Thus, target therapy for RAAS might bring additional beneficial effects on bone metabolic diseases such as osteoporosis, rheumatoid arthritis and vascular calcification other than blood pressure lowering effect.